Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota | Cancer Chemotherapy and Pharmacology
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia | Haematologica
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e1ff2ef8f89b7329a74a5a2ac322bba45bc00394/2-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia | PLOS ONE
The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells - ScienceDirect
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Cytarabine-resistant (320nM) acute myeloid leukemia (AML) MOLM-13 cell line
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
Pan‑RAF inhibitor LY3009120 is highly synergistic with low‑dose cytarabine, but not azacitidine, in acute myeloid leukemia with <em>RAS</em> mutations
RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia | Pharmacogenomics
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
How I treat older patients with acute myeloid leukemia
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
